US 12,083,204 B2
Topical composition for homeostatic delivery of nitric oxide and uses thereof
Jacob Waugh, Las Vegas, NV (US); and Jonah Shacknai, Santa Barbara, CA (US)
Assigned to L'OREAL, Paris (FR)
Filed by L'OREAL, Paris (FR); and Sisi Waugh, Las Vegas, NV (US)
Filed on Jun. 2, 2022, as Appl. No. 17/831,333.
Prior Publication US 2023/0390172 A1, Dec. 7, 2023
Int. Cl. A61K 8/40 (2006.01); A61K 8/19 (2006.01); A61K 8/44 (2006.01); A61K 8/49 (2006.01); A61K 8/60 (2006.01); A61K 8/64 (2006.01); A61K 8/67 (2006.01); A61K 8/9789 (2017.01); A61Q 19/08 (2006.01)
CPC A61K 8/40 (2013.01) [A61K 8/19 (2013.01); A61K 8/44 (2013.01); A61K 8/4946 (2013.01); A61K 8/4953 (2013.01); A61K 8/498 (2013.01); A61K 8/606 (2013.01); A61K 8/64 (2013.01); A61K 8/675 (2013.01); A61K 8/9789 (2017.08); A61Q 19/08 (2013.01)] 24 Claims
OG exemplary drawing
 
1. A topical composition for treating ageing-related skin conditions, comprising:
adenosine present from about 0.01 to about 0.5 wt %,
arginine present from about 0.1 to about 1.0 wt %,
carnosine present from about 0.05 to about 0.2 wt %,
niacinamide present from about 0.5 to about 6 wt %, and
a magnesium ion source present from about 0.1 to about 1.0 wt %,
wherein upon application of the composition to a skin region, a nitric oxide is produced or generated and increases cutaneous blood flow in the skin region compared to cutaneous blood flow in a similar skin region not treated with the composition, as measured by doppler ultrasound, and
wherein the composition is suitable for at least daily topical application to skin for a period of at least 32 days.